These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 19622344)
1. beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein. Kim YS; Lim D; Kim JY; Kang SJ; Kim YH; Im H Biochem Biophys Res Commun; 2009 Oct; 387(4):682-7. PubMed ID: 19622344 [TBL] [Abstract][Full Text] [Related]
2. The hexapeptide PGVTAV suppresses neurotoxicity of human α-synuclein aggregates. Choi MY; Kim YS; Lim D; Kang SJ; Kim YH; Lee K; Im H Biochem Biophys Res Commun; 2011 May; 408(2):334-8. PubMed ID: 21510923 [TBL] [Abstract][Full Text] [Related]
3. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants. Koo HJ; Choi MY; Im H Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571 [TBL] [Abstract][Full Text] [Related]
4. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968 [TBL] [Abstract][Full Text] [Related]
5. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides. Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459 [TBL] [Abstract][Full Text] [Related]
7. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. Ramakrishnan M; Jensen PH; Marsh D Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533 [TBL] [Abstract][Full Text] [Related]
8. Role of different regions of alpha-synuclein in the assembly of fibrils. Qin Z; Hu D; Han S; Hong DP; Fink AL Biochemistry; 2007 Nov; 46(46):13322-30. PubMed ID: 17963364 [TBL] [Abstract][Full Text] [Related]
9. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein. Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297 [TBL] [Abstract][Full Text] [Related]
10. Sequence determinants regulating fibrillation of human alpha-synuclein. Koo HJ; Lee HJ; Im H Biochem Biophys Res Commun; 2008 Apr; 368(3):772-8. PubMed ID: 18261982 [TBL] [Abstract][Full Text] [Related]
11. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis. Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751 [TBL] [Abstract][Full Text] [Related]
12. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein. Rekas A; Lo V; Gadd GE; Cappai R; Yun SI Macromol Biosci; 2009 Mar; 9(3):230-8. PubMed ID: 19116892 [TBL] [Abstract][Full Text] [Related]
13. Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: templation and inhibition involve oligomers with different structure. Horvath I; Sellstedt M; Weise C; Nordvall LM; Krishna Prasad G; Olofsson A; Larsson G; Almqvist F; Wittung-Stafshede P Arch Biochem Biophys; 2013 Apr; 532(2):84-90. PubMed ID: 23399432 [TBL] [Abstract][Full Text] [Related]
14. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein. Follmer C; Romão L; Einsiedler CM; Porto TC; Lara FA; Moncores M; Weissmüller G; Lashuel HA; Lansbury P; Neto VM; Silva JL; Foguel D Biochemistry; 2007 Jan; 46(2):472-82. PubMed ID: 17209557 [TBL] [Abstract][Full Text] [Related]
15. SDS-induced fibrillation of alpha-synuclein: an alternative fibrillation pathway. Giehm L; Oliveira CL; Christiansen G; Pedersen JS; Otzen DE J Mol Biol; 2010 Aug; 401(1):115-33. PubMed ID: 20540950 [TBL] [Abstract][Full Text] [Related]
16. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease. Kumar S; Sarkar A; Sundar D Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781 [TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Paleologou KE; Irvine GB; El-Agnaf OM Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056 [TBL] [Abstract][Full Text] [Related]
18. Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment. Kim HJ; Chatani E; Goto Y; Paik SR J Microbiol Biotechnol; 2007 Dec; 17(12):2027-32. PubMed ID: 18167451 [TBL] [Abstract][Full Text] [Related]
19. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Bharathi ; Indi SS; Rao KS Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865 [TBL] [Abstract][Full Text] [Related]
20. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. Ono K; Hirohata M; Yamada M J Neurosci Res; 2007 May; 85(7):1547-57. PubMed ID: 17387689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]